[go: up one dir, main page]

HUP0100197A3 - Compositions and vaccines to enhance an immune response of nucleic acid vaccination - Google Patents

Compositions and vaccines to enhance an immune response of nucleic acid vaccination

Info

Publication number
HUP0100197A3
HUP0100197A3 HU0100197A HUP0100197A HUP0100197A3 HU P0100197 A3 HUP0100197 A3 HU P0100197A3 HU 0100197 A HU0100197 A HU 0100197A HU P0100197 A HUP0100197 A HU P0100197A HU P0100197 A3 HUP0100197 A3 HU P0100197A3
Authority
HU
Hungary
Prior art keywords
vaccines
enhance
compositions
nucleic acid
immune response
Prior art date
Application number
HU0100197A
Other languages
English (en)
Original Assignee
Smithkline Beecham Biolog
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biolog filed Critical Smithkline Beecham Biolog
Publication of HUP0100197A2 publication Critical patent/HUP0100197A2/hu
Publication of HUP0100197A3 publication Critical patent/HUP0100197A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
HU0100197A 1997-12-16 1998-12-11 Compositions and vaccines to enhance an immune response of nucleic acid vaccination HUP0100197A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9726555.7A GB9726555D0 (en) 1997-12-16 1997-12-16 Vaccine
PCT/EP1998/008152 WO1999030733A1 (en) 1997-12-16 1998-12-11 Method to enhance an immune response of nucleic acid vaccination

Publications (2)

Publication Number Publication Date
HUP0100197A2 HUP0100197A2 (hu) 2001-05-28
HUP0100197A3 true HUP0100197A3 (en) 2003-11-28

Family

ID=10823687

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0100197A HUP0100197A3 (en) 1997-12-16 1998-12-11 Compositions and vaccines to enhance an immune response of nucleic acid vaccination

Country Status (18)

Country Link
US (2) US6500432B1 (hu)
EP (1) EP1037662A1 (hu)
JP (1) JP2002508333A (hu)
KR (1) KR20010024731A (hu)
CN (1) CN1284883A (hu)
AR (1) AR017866A1 (hu)
AU (1) AU740729B2 (hu)
BR (1) BR9814285A (hu)
CA (1) CA2313005A1 (hu)
GB (1) GB9726555D0 (hu)
HU (1) HUP0100197A3 (hu)
IL (1) IL136345A0 (hu)
NO (1) NO20003087L (hu)
NZ (1) NZ504936A (hu)
PL (1) PL341212A1 (hu)
TR (1) TR200001737T2 (hu)
WO (1) WO1999030733A1 (hu)
ZA (1) ZA9811501B (hu)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001007075A2 (en) * 1999-07-22 2001-02-01 Aventis Pharmaceuticals, Inc. Multi-dose erythropoietin formulations
WO2001012223A2 (en) 1999-08-19 2001-02-22 Dynavax Technologies Corporation Methods of modulating an immune response using immunostimulatory sequences and compositions for use therein
AU1013701A (en) * 1999-10-22 2001-05-08 Aventis Pasteur Limited Modified gp100 and uses thereof
FR2804026B1 (fr) * 2000-01-21 2004-06-11 Merial Sas Vaccination contre l'herpesvirose canine et vaccins
US7713942B2 (en) * 2001-04-04 2010-05-11 Nordic Vaccine Technology A/S Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides
CU23244A1 (es) * 2001-07-16 2007-10-17 Ct Ingenieria Genetica Biotech Formulacion vacunal potenciada por la combinacion de un adn con un antigeno
CA2436972A1 (en) * 2001-12-20 2003-07-03 Aventis Pasteur Limited Immunogenic compositions comprising an antigen and a purified m protein from respiratory syncytial virus
DK1490100T3 (da) * 2002-03-28 2012-03-12 Brenntag Biosector As Kombinerede DNA/proteinvaccinepræparater
AU2003244855A1 (en) 2002-07-05 2004-01-23 Lipoxen Technologies Limited Method to enhance an immune response of nucleic acid vaccination
US9200036B2 (en) 2002-07-12 2015-12-01 The Johns Hopkins University Mesothelin vaccines and model systems
WO2004006837A2 (en) * 2002-07-12 2004-01-22 The Johns Hopkins University Mesothelin vaccines and model systems
US20090110702A1 (en) 2002-07-12 2009-04-30 The Johns Hopkins University Mesothelin Vaccines and Model Systems and Control of Tumors
WO2004047861A1 (en) * 2002-11-26 2004-06-10 Eurocine Ab Vaccines against viruses with cationic substances as adjuvants
US8080642B2 (en) * 2003-05-16 2011-12-20 Vical Incorporated Severe acute respiratory syndrome DNA compositions and methods of use
CA2566355C (en) * 2004-05-18 2014-04-15 Vical Incorporated Influenza virus vaccine composition and methods of use
TW200613554A (en) 2004-06-17 2006-05-01 Wyeth Corp Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
CN101437547A (zh) * 2005-01-20 2009-05-20 自然科技公司 用于遗传免疫的载体和方法
WO2006110344A1 (en) * 2005-04-07 2006-10-19 Wyeth Novel methods for inducing an immune response against human immunodefiency virus
FR2893254B1 (fr) 2005-11-14 2007-12-21 Biomerieux Sa Composition comprenant un vecteur synthetique colloidal bioresorbable et un vecteur viral et son utilisation prophylactique, therapeutique et diagnostique.
US8652782B2 (en) 2006-09-12 2014-02-18 Longhorn Vaccines & Diagnostics, Llc Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acids
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US9109012B2 (en) * 2007-05-29 2015-08-18 Nature Technology Corporation Vectors and method for genetic immunization
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
WO2009029686A1 (en) 2007-08-27 2009-03-05 Longhorn Vaccines & Diagnostics Llc Immunogenic compositions and methods
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
AU2008343745B2 (en) 2007-10-01 2012-05-10 Longhorn Vaccines & Diagnostics Llc Biological specimen collection and transport system and methods of use
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
WO2009143167A2 (en) 2008-05-19 2009-11-26 Advaxis Dual delivery system for heterologous antigens
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
MX375965B (es) 2010-05-14 2025-03-07 Baxalta Inc Genes ospa quimericos, proteinas, y metodos para usar los mismos.
JP5940064B2 (ja) 2010-07-06 2016-06-29 ノバルティス アーゲー 低用量のｒｎａを用いた大型哺乳動物の免疫化
SI2590626T1 (sl) 2010-07-06 2016-01-29 Glaxosmithkline Biologicals S.A. Liposomi z lipidi, ki imajo koristno pKa vrednost, za dostavo RNA
SI3243526T1 (sl) 2010-07-06 2020-02-28 Glaxosmithkline Biologicals S.A. Dostava RNA za sprožitev večih imunskih poti
EP3970742B1 (en) 2010-08-31 2022-05-25 GlaxoSmithKline Biologicals S.A. Pegylated liposomes for delivery of immunogen-encoding rna
EP2621527A4 (en) 2010-10-01 2015-12-09 Univ Pennsylvania USE OF LISTERIA VACCINE VECTORS TO REVERSE VACCINE IMMUNITY IN PATIENTS WITH PARASITIC INFECTIONS
BR112013008700B8 (pt) 2010-10-11 2022-10-04 Novartis Ag Molécula de rna auto-replicante, partícula de replicon de alfavírus, composição, molécula de dna recombinante, uso da molécula de rna auto-replicante
EP2683400A4 (en) 2011-03-11 2014-09-17 Advaxis ADJUVANZIA ON LISTERIA BASE
US11058762B2 (en) 2011-07-06 2021-07-13 Glaxosmithkline Biologicals Sa Immunogenic compositions and uses thereof
EP3332802A1 (en) 2011-07-06 2018-06-13 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
EP3494989B1 (en) 2012-01-26 2025-07-16 Longhorn Vaccines and Diagnostics, LLC Composite antigenic sequences and vaccines
CN103239734B (zh) * 2012-02-10 2016-02-24 北京艾棣维欣生物技术有限公司 用于预防和/或治疗呼吸道合胞病毒感染的疫苗
CN104411327A (zh) 2012-03-12 2015-03-11 阿德瓦希斯公司 李斯特菌疫苗治疗以后的抑制细胞功能抑制
CN104640563A (zh) 2012-07-27 2015-05-20 巴克斯特国际公司 包含嵌合的ospa分子的组合物及其使用方法
MA40344A (fr) 2014-07-18 2016-01-21 Advaxis Inc Combinaison d'un antagoniste de pd-1 et d'un vaccin à base de listeria pour le traitement du cancer
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
EP3294448A4 (en) 2015-05-14 2018-12-12 Longhorn Vaccines and Diagnostics, LLC Rapid methods for the extraction of nucleic acids from biological samples
WO2019051642A1 (zh) * 2017-09-12 2019-03-21 广州中科蓝华生物科技有限公司 一种转染细胞内寄生虫的试剂盒及其应用
SG11202002157TA (en) 2017-09-19 2020-04-29 Advaxis Inc Compositions and methods for lyophilization of bacteria or listeria strains
EP4168593A4 (en) 2020-06-23 2024-11-27 The Regents of the University of Colorado, a body corporate METHODS FOR DIAGNOSIS OF RESPIRATORY PATHOGENS AND PREDICTION OF EVOLUTIONS ASSOCIATED WITH COVID-19
KR20230091978A (ko) 2020-10-20 2023-06-23 롱혼 백신즈 앤드 다이어그나스틱스, 엘엘씨 면역원성 항원

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6168804B1 (en) * 1995-06-07 2001-01-02 University Of Alberta Method for eliciting Th1-specific immune response
ATE225668T1 (de) * 1996-02-12 2002-10-15 Cobra Therapeutics Ltd Neue methode zur impfung sowie impfstoffe dafür, die eine epitopkodierende nukleinsäure und ein epitopenthaltende peptid beinhalten
US6093400A (en) * 1996-08-09 2000-07-25 Cel Sci Corporation Modified HGP-30 peptides, conjugates, compositions and methods of use

Also Published As

Publication number Publication date
AR017866A1 (es) 2001-10-24
BR9814285A (pt) 2000-10-03
PL341212A1 (en) 2001-03-26
AU740729B2 (en) 2001-11-15
AU1967899A (en) 1999-07-05
CN1284883A (zh) 2001-02-21
IL136345A0 (en) 2001-05-20
ZA9811501B (en) 2000-06-15
HUP0100197A2 (hu) 2001-05-28
NO20003087D0 (no) 2000-06-15
TR200001737T2 (tr) 2000-12-21
US6500432B1 (en) 2002-12-31
KR20010024731A (ko) 2001-03-26
NO20003087L (no) 2000-08-08
GB9726555D0 (en) 1998-02-11
US20030072768A1 (en) 2003-04-17
CA2313005A1 (en) 1999-06-24
JP2002508333A (ja) 2002-03-19
EP1037662A1 (en) 2000-09-27
WO1999030733A1 (en) 1999-06-24
NZ504936A (en) 2002-09-27

Similar Documents

Publication Publication Date Title
HUP0100197A3 (en) Compositions and vaccines to enhance an immune response of nucleic acid vaccination
AU6226100A (en) Inducing cellular immune responses to hepatitis c virus using peptide and nucleic acid compositions
HU9502105D0 (en) Vaccine compositions and method for induction of mucosal immune response via systemic vaccination
RS50325B (sr) Imunostimulatorne nukleinske kiseline
ZA979320B (en) Nucleic acid vaccines against rickettsial diseases and methods of use
HUP0103085A3 (en) Formulations an processes for inducing an immune response to polysaccharide
FR07C0064I1 (fr) Produits d'addition et vaccins
AU4231897A (en) Compositions and methods for delivery of nucleic acids to hepatocytes
AU2001241918A1 (en) Methods of enhancing activity of vaccines and vaccine compositions
AU2773695A (en) Compositions for and methods of enhancing delivery of nucleic acids to cells
AU2002249852A1 (en) Enhancement of immune response to vaccine by interferon alpha
HUP0100267A3 (en) Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof
HUP0104881A3 (en) Method to produce inactivated w/o emulsion adjuvated vaccines
EP1017283A4 (en) POLYNUCLEOTIDE VACCINE FORMULATIONS
IL129397A0 (en) Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof
IL129746A0 (en) Nucleic acid and amino acid sequences relating to helicobacter pylori and vaccine compositions thereof
PL332856A1 (en) Methods of and compositions for delivery and expression of nucleic acids as needed by interferon
IL115671A0 (en) Use of protease inhibitors and protease vaccines to protect animals from flea infestation and flea protease proteins nucleic acid molecules and uses thereof
HUP0400492A3 (en) Nucleic acids of the human abc1 gene and applications thereof
EP0686039A4 (en) METHOD FOR IMPROVING THE IMMUNE RESPONSE TO ORAL VACCINES
DE69830156D1 (de) Zusammensetzungen zur immunverstärkung von impfstoffen
EP1220896A4 (en) NEW HUMANE LIPASE PROTEINS, FOR CODING NUCLEIC ACIDS AND THEIR USE
HK1032196A (en) Method to enhance an immune response of nucleic acid vaccination
WO2000065063A3 (en) Nucleic acid vaccines against rickettsial diseases and methods of use
AU2001253029A1 (en) T-cell epitope of mage-12 and related nucleic acids, vectors, cells, compositions and methods of inducing an immune response to cancer